Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BNT162
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : BioNTech
Deal Size : Undisclosed
Deal Type : Agreement
Details : Rentschler Biopharma will be responsible for key aspects of cGMP drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech, and is currently in a global Phase 3 clinical trial.
Product Name : BNT162
Product Type : Vaccine
Upfront Cash : Undisclosed
July 10, 2020
Lead Product(s) : BNT162
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : BioNTech
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
